{"id":"https://openalex.org/W1949762012","doi":"https://doi.org/10.1046/j.1365-2125.2000.00208.x","title":"Antihypertensive drugs and the risk of idiopathic aplastic anaemia","display_name":"Antihypertensive drugs and the risk of idiopathic aplastic anaemia","publication_year":2000,"publication_date":"2000-06-01","ids":{"openalex":"https://openalex.org/W1949762012","doi":"https://doi.org/10.1046/j.1365-2125.2000.00208.x","mag":"1949762012","pmid":"https://pubmed.ncbi.nlm.nih.gov/10848725","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2015046"},"language":"en","primary_location":{"id":"doi:10.1046/j.1365-2125.2000.00208.x","doi":"https://doi.org/10.1046/j.1365-2125.2000.00208.x","is_oa":true,"landing_page_url":"https://doi.org/10.1046/j.1365-2125.2000.00208.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.2000.00208.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.2000.00208.x","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5086707051","display_name":"Marian Wald Myers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I111088046","display_name":"Boston University","ror":"https://ror.org/05qwgg493","country_code":"US","type":"education","lineage":["https://openalex.org/I111088046"]},{"id":"https://openalex.org/I4210115736","display_name":"Boston Collaborative Drug Surveillance Program","ror":"https://ror.org/0228drn10","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210115736"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marian Wald Myers","raw_affiliation_strings":["The Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, 11 Muzzey Street, Lexington, MA 02421, USA","The Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, 11 Muzzey Street, Lexington, MA 02421, USA and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, 11 Muzzey Street, Lexington, MA 02421, USA","institution_ids":["https://openalex.org/I111088046","https://openalex.org/I4210115736"]},{"raw_affiliation_string":"The Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, 11 Muzzey Street, Lexington, MA 02421, USA and","institution_ids":["https://openalex.org/I111088046","https://openalex.org/I4210115736"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066275631","display_name":"Catherine Vasilakis\u2010Scaramozza","orcid":"https://orcid.org/0000-0002-8721-4604","observed_orcids":["https://orcid.org/0000-0002-8721-4604"]},"institutions":[{"id":"https://openalex.org/I111088046","display_name":"Boston University","ror":"https://ror.org/05qwgg493","country_code":"US","type":"education","lineage":["https://openalex.org/I111088046"]},{"id":"https://openalex.org/I4210115736","display_name":"Boston Collaborative Drug Surveillance Program","ror":"https://ror.org/0228drn10","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210115736"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Catherine Vasilakis","raw_affiliation_strings":["The Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, 11 Muzzey Street, Lexington, MA 02421, USA and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, 11 Muzzey Street, Lexington, MA 02421, USA and","institution_ids":["https://openalex.org/I111088046","https://openalex.org/I4210115736"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Matthew R. Kaufman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew R. Kaufman","raw_affiliation_strings":["From the Department of Medicine, Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Department of Medicine, Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065681509","display_name":"Hershel Jick","orcid":"https://orcid.org/0000-0003-4270-5992","observed_orcids":["https://orcid.org/0000-0003-4270-5992"]},"institutions":[{"id":"https://openalex.org/I111088046","display_name":"Boston University","ror":"https://ror.org/05qwgg493","country_code":"US","type":"education","lineage":["https://openalex.org/I111088046"]},{"id":"https://openalex.org/I4210115736","display_name":"Boston Collaborative Drug Surveillance Program","ror":"https://ror.org/0228drn10","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210115736"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hershel Jick","raw_affiliation_strings":["The Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, 11 Muzzey Street, Lexington, MA 02421, USA and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, 11 Muzzey Street, Lexington, MA 02421, USA and","institution_ids":["https://openalex.org/I111088046","https://openalex.org/I4210115736"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4780,"currency":"USD","value_usd":4780},"apc_paid":null,"fwci":0.8654,"has_fulltext":true,"cited_by_count":12,"citation_normalized_percentile":{"value":0.70448961,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"49","issue":"6","first_page":"604","last_page":"608"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.5863999724388123,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.5863999724388123,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13374","display_name":"Hematological disorders and diagnostics","score":0.3345000147819519,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12919","display_name":"Blood disorders and treatments","score":0.031099999323487282,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antihypertensive-drugs","display_name":"antihypertensive drugs","score":0.953000009059906},{"id":"https://openalex.org/keywords/calcium-channel-blockers","display_name":"calcium channel blockers","score":0.9010000228881836},{"id":"https://openalex.org/keywords/nifedipine","display_name":"nifedipine","score":0.9980000257492065},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6060000061988831},{"id":"https://openalex.org/keywords/beta-blockers","display_name":"beta-blockers","score":0.9110000133514404},{"id":"https://openalex.org/keywords/ace-inhibitors","display_name":"ACE inhibitors","score":0.9269999861717224}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8953880071640015},{"id":"https://openalex.org/C2779066535","wikidata":"https://www.wikidata.org/wiki/Q39111","display_name":"Nifedipine","level":3,"score":0.7762501239776611},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.6965664029121399},{"id":"https://openalex.org/C146304588","wikidata":"https://www.wikidata.org/wiki/Q961652","display_name":"Case-control study","level":2,"score":0.5753545761108398},{"id":"https://openalex.org/C2781440808","wikidata":"https://www.wikidata.org/wiki/Q846316","display_name":"Aplastic anemia","level":3,"score":0.5559697151184082},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5530826449394226},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4661594331264496},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3869471549987793},{"id":"https://openalex.org/C519063684","wikidata":"https://www.wikidata.org/wiki/Q706","display_name":"Calcium","level":2,"score":0.23731625080108643},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000741","descriptor_name":"Anemia, Aplastic","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D000741","descriptor_name":"Anemia, Aplastic","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D002121","descriptor_name":"Calcium Channel Blockers","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006113","descriptor_name":"United Kingdom","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009543","descriptor_name":"Nifedipine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016017","descriptor_name":"Odds Ratio","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016022","descriptor_name":"Case-Control Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016208","descriptor_name":"Databases, Factual","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1046/j.1365-2125.2000.00208.x","doi":"https://doi.org/10.1046/j.1365-2125.2000.00208.x","is_oa":true,"landing_page_url":"https://doi.org/10.1046/j.1365-2125.2000.00208.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.2000.00208.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:10848725","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10848725","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Comparative Study"},{"id":"pmh:oai:pubmedcentral.nih.gov:2015046","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2015046/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Clin Pharmacol","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1046/j.1365-2125.2000.00208.x","doi":"https://doi.org/10.1046/j.1365-2125.2000.00208.x","is_oa":true,"landing_page_url":"https://doi.org/10.1046/j.1365-2125.2000.00208.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.2000.00208.x","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1949762012.pdf","grobid_xml":"https://content.openalex.org/works/W1949762012.grobid-xml"},"referenced_works_count":10,"referenced_works":["https://openalex.org/W1967780760","https://openalex.org/W1996239854","https://openalex.org/W2040492681","https://openalex.org/W2041723789","https://openalex.org/W2075996262","https://openalex.org/W2157604999","https://openalex.org/W2161974756","https://openalex.org/W2167819308","https://openalex.org/W4248141768","https://openalex.org/W4376597380"],"related_works":["https://openalex.org/W2161974756","https://openalex.org/W4210876207","https://openalex.org/W2046303635","https://openalex.org/W2734433444","https://openalex.org/W2083881398","https://openalex.org/W1974149808","https://openalex.org/W2005287271","https://openalex.org/W1993755867","https://openalex.org/W2137297294","https://openalex.org/W2779783847"],"abstract_inverted_index":{"AIMS:":[0],"A":[1],"recent":[2],"report":[3],"has":[4],"raised":[5],"concern":[6],"that":[7,38,276],"nifedipine":[8],"may":[9],"be":[10],"associated":[11,285],"with":[12,37,62,263,269,286],"an":[13,287],"increased":[14,288],"risk":[15,25,95,129,154,289],"of":[16,26,32,39,67,83,97,130,146,155,198,206,248,260,279,290],"aplastic":[17,28,84,98,132,150,156,291],"anaemia.":[18,151,292],"This":[19],"large":[20],"population-based":[21],"study":[22,45,61,274],"evaluated":[23],"the":[24,52,107,128,203,212,277],"idiopathic":[27,131,149],"anaemia":[29,85,99,133,157],"in":[30],"users":[31,161,197,247,259],"calcium":[33,169,222,265,280],"channel":[34,170,223,266,281],"blockers":[35,282],"compared":[36,127,268],"other":[40,199,249],"antihypertensive":[41,73,104,136,200,250],"drugs.":[42,74,105,201],"METHODS:":[43],"The":[44,94,152,272],"was":[46,100,162,215],"based":[47],"on":[48,118],"information":[49],"derived":[50],"from":[51],"General":[53],"Practice":[54],"Research":[55],"Database.":[56],"We":[57],"conducted":[58],"a":[59,63,80,264],"follow-up":[60],"nested":[64,108],"case-control":[65,109,204],"analysis":[66,205],"322":[68],"448":[69],"subjects":[70],"who":[71,78],"received":[72],"Cases":[75],"were":[76,113,143],"people":[77],"had":[79],"first-time":[81],"diagnosis":[82],"during":[86],"January":[87],"1,":[88],"1988":[89],"through":[90],"September":[91],"30,":[92],"1997.":[93],"estimate":[96],"calculated":[101],"for":[102,134,168,177,185,196,221,230,238,246,258],"all":[103,135],"For":[106],"analysis,":[110],"six":[111],"controls":[112],"matched":[114],"to":[115,139],"each":[116],"case":[117],"age,":[119],"sex":[120],"and":[121,190,209,252],"general":[122],"practice":[123],"attended.":[124],"Odds":[125],"ratios":[126],"drugs":[137,251,262],"relative":[138],"nonusers.":[140,270],"RESULTS:":[141],"There":[142],"13":[144,207],"cases":[145,208],"newly":[147],"diagnosed":[148],"estimated":[153],"per":[158],"100":[159],"000":[160],"0.8":[163],"(95%":[164,173,181,192,217,226,234,242,254],"CI":[165,174,182,193,218,227,235,243,255],"0.1,":[166,228,236,244,256],"4.7)":[167],"blockers,":[171,179,224,232],"1.4":[172],"0.5,":[175],"4.1)":[176],"beta-adrenoceptor":[178,231],"2.3":[180],"0.6,":[183],"8.6)":[184],"angiotension-converting":[186],"enzyme":[187],"(ACE)":[188],"inhibitors":[189],"5.9":[191],"1.6,":[194],"21.5)":[195],"In":[202],"77":[210],"controls,":[211],"odds":[213],"ratio":[214],"0.3":[216],"0.02,":[219],"3.3)":[220],"0.5":[225],"2.5)":[229],"0.7":[233,253],"5.6)":[237],"ACE":[239],"inhibitors,":[240],"1.2":[241],"11.8)":[245],"7.2)":[257],"multiple":[261],"blocker":[267],"CONCLUSIONS:":[271],"present":[273],"suggests":[275],"use":[278],"is":[283],"not":[284]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2014,"cited_by_count":2}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}